Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome

Eliano Pio Navarese, Volker Schulze, Felicita Andreotti, Mariusz Kowalewski, Michalina Kołodziejczak, David E. Kandzari, Tienush Rassaf, Bartosz Gorny, Maximilian Brockmeyer, Christian Meyer, Sergio Berti, Jacek Kubica, Malte Kelm, Marco Valgimigli

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The aim of this meta-analysis was to compare the 30-day safety and efficacy of bivalirudin with those of heparin with or without routine administration of a glycoprotein IIb/IIIa inhibitor (GPI) in patients with acute coronary syndrome (ACS).
Original languageEnglish
Pages (from-to)201-213
Number of pages13
JournalJACC: Cardiovascular Interventions
Volume8
DOIs
Publication statusPublished - 2015

Keywords

  • GP IIb/IIIa inhibitor
  • acute coronary syndrome
  • bivalirudin
  • heparin
  • meta-analysis

Fingerprint

Dive into the research topics of 'Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome'. Together they form a unique fingerprint.

Cite this